Development and validation of a tissue cage model of acute inflammation in the cat

Authors


L. Pelligand, Royal Veterinary College, Hawkshead Campus, Hatfield, Hertfordshire AL9 7TA, UK. E-mail: lpelligand@rvc.ac.uk

Abstract

Pelligand, L., House, A. K., Summers, B. A., Hatzis, A., Tivers, M., Elliott, J., Lees, P. Development and validation of a tissue cage model of acute inflammation in the cat. J. vet. Pharmacol. Therap. 35, 239–248.

Four cylindrical silicon tissue cages (TC, internal volume: 6.7 ± 0.11 cm3) were inserted subcutaneously in 29 young healthy cats. A mild inflammatory reaction was induced by intracaveal injection of 1 mL of a 2%λ-carrageenan solution. TC exudate was subsequently sampled at predetermined times (up to 120 h) to measure exudate leucocyte counts and the concentrations of protein and eicosanoids. TC remained in situ for 9–10 months and were well tolerated. Leucocyte counts peaked at 34 h (50.1 ± 57.6 × 103 cells/mm3) and returned towards baseline after 72 h. Protein concentration increased from 26.2 ± 2.7 g/L to a peak of 35.9 ± 6.0 g/L at 12 h before returning to baseline at 48 h. Exudate prostaglandin (PG)E2 concentration peaked at 24 h (11.7 ± 13.7 ng/mL) and returned to baseline by 120 h. Repeated collection of fluid from noninjected cages did not increase transudate PGE2. Ketoprofen (2 mg/kg, subcutaneously) suppressed exudate PGE2 at 24 h. The carrageenan-stimulated TC model is an ethical and novel means of investigating soft tissue inflammation in the cat, in which exudate PGE2 acts as surrogate marker of cyclooxygenase-2 activity. This model will facilitate the investigation of in vivo pharmacokinetics and pharmacodynamics of anti-inflammatory drugs in this species.

Ancillary